MacAlpine, Jessie
Daniel-Ivad, Martin http://orcid.org/0000-0001-6747-660X
Liu, Zhongle
Yano, Junko
Revie, Nicole M.
Todd, Robert T.
Stogios, Peter J.
Sanchez, Hiram http://orcid.org/0000-0002-6286-650X
O’Meara, Teresa R. http://orcid.org/0000-0002-8901-0154
Tompkins, Thomas A. http://orcid.org/0000-0002-2990-2265
Savchenko, Alexei
Selmecki, Anna
Veri, Amanda O.
Andes, David R. http://orcid.org/0000-0002-7927-9950
Fidel, Paul L. Jr.
Robbins, Nicole
Nodwell, Justin http://orcid.org/0000-0001-7909-1803
Whitesell, Luke http://orcid.org/0000-0001-6445-5766
Cowen, Leah E. http://orcid.org/0000-0001-5797-0110
Funding for this research was provided by:
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (EGP 491919-15)
Article History
Received: 6 August 2021
Accepted: 1 October 2021
First Online: 22 October 2021
Competing interests
: L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for development of novel antifungal therapeutics. L.E.C. is a consultant for Boragen, a small-molecule development company focused on leveraging the unique chemical properties of boron chemistry for crop protection and animal health. T.A.T. is an employee of Rosell Institute for Microbiome and Probiotics, the research arm of Lallemand Health Solutions, a company researching, manufacturing, and selling probiotic microbes. The remaining authors declare no competing interests.